Cogent Biosciences (COGT) Amortizatization of Intangibles (2017 - 2026)
Cogent Biosciences (COGT) posted quarterly Amortizatization of Intangibles of $1.2 million for Q1 2026, up 23.56% year-over-year from $955000.0 in Q1 2025, and up 11.74% quarter-over-quarter from $1.1 million in Q4 2025.
Powered by 
Analysis
Cogent Biosciences (COGT) Amortizatization of Intangibles (2017 - 2026) Analysis & Trends
Cogent Biosciences (COGT) has reported Amortizatization of Intangibles for 8 consecutive years, with $1.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortizatization of Intangibles rose 23.56% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $2.2 million (down 69.53% YoY), while the FY2025 annual figure was $2.0 million, down 74.25% from the prior year.
- Amortizatization of Intangibles grew to $1.2 million in Q1 2026 per COGT's latest filing, from $1.1 million in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $6.2 million in Q3 2024 and bottomed at -$2.6 million in Q2 2024.
- Historically, Amortizatization of Intangibles has averaged $1.2 million across 5 years, with a median of $1.0 million in 2023.
- On a YoY basis, Amortizatization of Intangibles climbed as much as 782.07% in 2024 and fell as far as 450.2% in 2024.
- Cogent Biosciences' Amortizatization of Intangibles stood at $1.2 million in 2022, then soared by 263.96% to $4.3 million in 2023, then tumbled by 39.47% to $2.6 million in 2024, then plunged by 59.45% to $1.1 million in 2025, then climbed by 11.74% to $1.2 million in 2026.
- Business Quant data shows COGT's Amortizatization of Intangibles at $1.2 million in Q1 2026, $1.1 million in Q4 2025, and $167000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Cogent Biosciences | 5.94 Bn | 5.94 Bn | - | 961,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 961,000.00 |
| Mar 31, 2026 | 1.18 Mn |
| Dec 31, 2025 | 513,000.00 |
| Sep 30, 2025 | 506,000.00 |
| Jun 30, 2025 | 45,000.00 |
| Mar 31, 2025 | 955,000.00 |
| Dec 31, 2024 | 2.60 Mn |
| Sep 30, 2024 | 6.20 Mn |
| Jun 30, 2024 | -2.58 Mn |
| Mar 31, 2024 | 1.40 Mn |
| Dec 31, 2023 | 4.05 Mn |
| Sep 30, 2023 | -658,000.00 |
| Jun 30, 2023 | 737,000.00 |
| Mar 31, 2023 | 1.04 Mn |
| Dec 31, 2022 | 517,000.00 |
| Sep 30, 2022 | 3.46 Mn |
| Jun 30, 2022 | 573,000.00 |
| Mar 31, 2022 | 491,000.00 |
| Dec 31, 2021 | 478,000.00 |
| Sep 30, 2021 | 466,000.00 |